Spike S1 RBD (B.1.1.7, Alpha Variant) (N501Y) (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit
The Spike S1 RBD (B.1.1.7 Variant) (N501Y) (SARS-CoV-2):ACE2 Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the B.1.1.7 Variant (N501Y) of the SARS-CoV-2 Spike S1 RBD protein. This kit comes in a convenient 96-well format, with purified SARS-CoV-2 Spike RBD B.1.1.7 Variant (N501Y) and ACE2-Biotin proteins, streptavidin-HRP, chemiluminescence HRP substrate, and assay buffer for 100 binding reactions. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike S1 RBD protein B.1.1.7 Variant is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike S1 RBD B.1.1.7 Variant on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a luminometer or microplate reader capable of reading chemiluminescence.
Assay Principle
PBS (Phosphate buffered saline)
Rotating or rocker platform
Microplate reader capable of reading chemiluminescence
| Catalog | Name | Amount | Storage |
| Spike S1 RBD (N501Y), His-tag (SARS-CoV-2) | 5 µg | -80°C | |
| 100665 | ACE2, His-Avi-Tag, Biotin-labeled HiP™ | 5 µg | -80°C |
| 79742 | Streptavidin-HRP | 15 µl | +4°C |
| 79311 | 3x Immuno Buffer 1 | 50 ml | -20°C |
| 79728 | Blocking Buffer 2 | 50 ml | +4°C |
| 79670 | ELISA ECL Substrate A (translucent bottle) | 6 ml | Room Temp |
| 79670 | ELISA ECL Substrate B (brown bottle) |
6 ml | Room Temp |
| 79699 | Transparent 96-well white microplate | 1 | Room Temp |
The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 offer promising protection against the viral infection. However recent reports showed that a mutant strain first identified in the UK (B1.1.7) exhibits higher transmissibility and infectivity. Investigations on the effects of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.
1. Wang P. et al., Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv 2021 Jan 26; 2021.01.25.428137
2. Shen X., et al., SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv. 2021 Jan 29; 2021.01.27.428516
3. Hoffman M. et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:1-10
Application References:
1. Inhibition of the Binding of Variants of SARS-CoV-2 Coronavirus Spike Protein to a Human Receptor by Chlorine Dioxide (2021)
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.